Top

Published in:

01-01-2025 | Platelet Rich Plasma Therapy | Review

Use of platelet-rich plasma in rheumatic diseases

Authors: Marlen Yessirkepov, Yuliya Fedorchenko, Olena Zimba, Ulzhan Mukanova

Published in: Rheumatology International | Issue 1/2025

Abstract

Platelet-rich plasma (PRP) has gained increasing recognition as a promising therapeutic agent in managing rheumatic diseases. Conventional treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), primarily act on reducing inflammation but fail to address the underlying mechanisms of connective tissue degradation. PRP, an autologous preparation enriched with growth factors and bioactive molecules, is pivotal in modulating inflammation and fostering tissue regeneration. This review overviews the therapeutic potential of PRP across a spectrum of rheumatic diseases, such as osteoarthritis (OA), rheumatoid arthritis (RA), systemic sclerosis (SSc), and osteonecrosis. The regenerative capacity of PRP, driven by vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β), promotes tissue repair, reduces cartilage damage and improves joint function. Emerging evidence supports the efficacy of PRP in early-stage OA, demonstrating superior outcomes over traditional therapies like hyaluronic acid and glucocorticoids in terms of pain relief and functional improvement. Despite its benefits, PRP therapy is characterized by variability in treatment responses, with challenges in standardizing preparation protocols and treatment regimens. This review highlights the need for robust clinical trials to establish uniform treatment protocols, optimize patient selection, and evaluate the long-term clinical outcomes of PRP therapy in rheumatic diseases.

Fedorchenko Y, Zimba O, Yatsyshyn R, Doskaliuk B, Zaiats L, Fedorchenko M (2024) The interplay between rheumatic diseases and pulmonary health. Rheumatol Int 44:1179–1184. https://doi.org/10.1007/s00296-024-05565-wCrossRefPubMed

Bobek D, Banić Stipetić A, Franić M, Lucijanić M, Lucijanić J, Gudelj Gračanin A, Mijačika L, Perić P (2022) Use of non-steroidal anti-inflammatory drugs in patients with advanced active rheumatoid arthritis. Acta Clin Croat 61:588–598. https://doi.org/10.20471/acc.2022.61.04.04CrossRefPubMedPubMedCentral

Gasparyan AY, Ayvazyan L, Pretorius E, Kitas GD (2014) Platelets in rheumatic diseases: friend or foe? Curr Pharm Des 20:552–566. https://doi.org/10.2174/138161282004140213143843CrossRefPubMed

Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Douglas KM, Kitas GD (2011) Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 31:153–164. https://doi.org/10.1007/s00296-010-1446-xCrossRefPubMed

Ntelis K, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D (2019) Platelets in systemic sclerosis: the Missing Link connecting Vasculopathy, Autoimmunity, and fibrosis? Curr Rheumatol Rep 21:15. https://doi.org/10.1007/s11926-019-0815-zCrossRefPubMed

Robert M, Scherlinger M (2024) Platelets are a major player and represent a therapeutic opportunity in systemic lupus erythematosus. Joint Bone Spine 91:105622. https://doi.org/10.1016/j.jbspin.2023.105622CrossRefPubMed

Xiao Z, Chen W, Wei Z, Zhang Q, Tang G (2023) Global trends and hotspots in the application of platelet-rich plasma in knee osteoarthritis: a bibliometric analysis from 2008 to 2022. Med (Baltim) 102:e35854. https://doi.org/10.1097/MD.0000000000035854CrossRef

Tian J, Li XJ, Ma Y, Mai Z, Yang Y, Luo M et al (2023) Correlation of bioactive components of platelet rich plasma derived from human female adult peripheral blood and umbilical cord blood with age. Sci Rep 13:18428. https://doi.org/10.1038/s41598-023-45747-3CrossRefPubMedPubMedCentral

Chellamuthu G, Muthu S, Khanna M, Khanna V (2021) Platelet-rich plasma holds promise in management of rheumatoid arthritis’-systematic review. Rheumatol Int 41:1895–1903. https://doi.org/10.1007/s00296-021-04849-9CrossRefPubMed

10.

Saif DS, Hegazy NN, Zahran ES (2021) Evaluating the efficacy of intra-articular injections of platelet Rich plasma (PRP) in rheumatoid arthritis patients and its impact on inflammatory cytokines, Disease Activity and Quality of Life. Curr Rheumatol Rev 17:232–241. https://doi.org/10.2174/1573397116666201113090629CrossRefPubMed

11.

Tong S, Zhang C, Liu J (2017) Platelet-rich plasma exhibits beneficial effects for rheumatoid arthritis mice by suppressing inflammatory factors. Mol Med Rep 16:4082–4088. https://doi.org/10.3892/mmr.2017.7091CrossRefPubMed

12.

Hurley ET, Sherman SL, Stokes DJ, Rodeo SA, Shapiro SA, Mautner K et al (2024) Experts achieve Consensus on a majority of statements regarding platelet-rich plasma treatments for treatment of Musculoskeletal Pathology. Arthroscopy 40:470–477. https://doi.org/10.1016/j.arthro.2023.08.020CrossRefPubMed

13.

Boswell SG, Cole BJ, Sundman EA, Karas V, Fortier LA (2012) Platelet-rich plasma: a milieu of bioactive factors. Arthroscopy 28:429–439. https://doi.org/10.1016/j.arthro.2011.10.018CrossRefPubMed

14.

Chalidis B, Givissis P, Papadopoulos P, Pitsilos C (2023) Molecular and Biologic effects of platelet-rich plasma (PRP) in ligament and Tendon Healing and Regeneration: a systematic review. Int J Mol Sci 24:2744. https://doi.org/10.3390/ijms24032744CrossRefPubMedPubMedCentral

15.

Kale P, Patel H, Jaiswal AM (2024) Mechanisms, efficacy, and clinical applications of platelet-rich plasma in Tendinopathy. Compr Rev Cureus 16:e65636. https://doi.org/10.7759/cureus.65636CrossRef

16.

Zhou Y, Wang JH (2016) PRP treatment efficacy for Tendinopathy: a review of Basic Science studies. Biomed Res Int 2016(9103792). https://doi.org/10.1155/2016/9103792

17.

Kennedy MI, Whitney K, Evans T, LaPrade RF (2018) Platelet-Rich plasma and cartilage repair. Curr Rev Musculoskelet Med 11:573–582. https://doi.org/10.1007/s12178-018-9516-xCrossRefPubMedPubMedCentral

18.

Mariani E, Roffi A, Cattini L, Pulsatelli L, Assirelli E, Krishnakumar GS (2020) Release kinetic of pro- and anti-inflammatory biomolecules from platelet-rich plasma and functional study on osteoarthritis synovial fibroblasts. Cytotherapy 22:344–353. https://doi.org/10.1016/j.jcyt.2020.02.006CrossRefPubMed

19.

Moeda F, Melo X, Hatia M, Pinho S, Calado D, Branco JC, Gonçalves MJ (2022) The effects of intra-articular platelet-rich plasma injections in rheumatoid arthritis: a narrative review. Cureus 14:e28182. https://doi.org/10.7759/cureus.28182CrossRefPubMedPubMedCentral

20.

Shively D, Amin N (2021) Platelet-Rich plasma for rheumatoid arthritis: a Case Series. Cureus 13:e19629. https://doi.org/10.7759/cureus.19629CrossRefPubMedPubMedCentral

21.

Andia I, Maffulli N (2013) Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol 9:721–730. https://doi.org/10.1038/nrrheum.2013.141CrossRefPubMed

22.

Bastawy EM, Zaki MG, Badr N, Abdallah F, El-Gharbawy NH (2024) Assessment of synovial repair in primary knee osteoarthritis after platelet rich plasma (PRP) intra-articular injection. Egypt J Immunol 31:58–65 PMID: 39417741CrossRefPubMed

23.

Ghorbani O, Mahdibarzi D, Yousefi-Tooddeshki P (2024) Comparison of the short-term effect of intra-articular hyaluronic acid and platelet-rich plasma injections in knee osteoarthritis: a randomized clinical trial. J Prev Med Hyg 65:E214–E220. https://doi.org/10.15167/2421-4248/jpmh2024.65.2.3270CrossRefPubMedPubMedCentral

24.

Pabinger C, Kobinia GS, Dammerer D (2024) Injection therapy in knee osteoarthritis: cortisol, hyaluronic acid, PRP, or BMAC (mesenchymal stem cell therapy)? Front Med (Lausanne) 11:1463997. https://doi.org/10.3389/fmed.2024.1463997CrossRefPubMed

25.

Berrigan W, Tao F, Kopcow J, Park AL, Allen I, Tahir P, Reddy A, Bailowitz Z (2024) The effect of platelet dose on outcomes after platelet Rich plasma injections for Musculoskeletal conditions: a systematic review and Meta-analysis. Curr Rev Musculoskelet Med. https://doi.org/10.1007/s12178-024-09922-xCrossRefPubMedPubMedCentral

26.

Lin W, Xie L, Zhou L, Zheng J, Zhai W, Lin D (2023) Effects of platelet-rich plasma on subchondral bone marrow edema and biomarkers in synovial fluid of knee osteoarthritis. Knee 42:161–169. https://doi.org/10.1016/j.knee.2023.03.002CrossRefPubMed

27.

Giuseppe Milano M, Sánchez, Chris H, Jo MF, Saccomanno, Bhavani P, Thampatty, James H-C, Wang (2019) Platelet-rich plasma in orthopaedic sports medicine: state of the art. J ISAKOS 4:188–195CrossRef

28.

Rossi LA, Brandariz R, Gorodischer T, Camino P, Piuzzi N, Tanoira I, Ranalletta M (2024) Subacromial injection of platelet-rich plasma provides greater improvement in pain and functional outcomes compared to corticosteroids at 1-year follow-up: a double-blinded randomized controlled trial. J Shoulder Elb Surg. https://doi.org/10.1016/j.jse.2024.06.012CrossRef

29.

Lu J, Li H, Zhang Z, Xu R, Wang J, Jin H (2023) Platelet-rich plasma in the pathologic processes of tendinopathy: a review of basic science studies. Front Bioeng Biotechnol 11:1187974. https://doi.org/10.3389/fbioe.2023.1187974CrossRefPubMedPubMedCentral

30.

Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409. https://doi.org/10.1007/s00296-011-1999-324CrossRefPubMed

31.

Hunter DJ, Bierma-Zeinstra S (2019) Osteoarthritis. Lancet 393(10182):1745–1759. https://doi.org/10.1016/S0140-6736(19)30417-9CrossRefPubMed

32.

Zhuang W, Li T, Li Y, Zhang Y, Gao J, Wang X, Ding Q, Li W (2024) The varying clinical effectiveness of single, three and five intraarticular injections of platelet-rich plasma in knee osteoarthritis. J Orthop Surg Res 19(1):284. https://doi.org/10.1186/s13018-024-04736-6CrossRefPubMedPubMedCentral

33.

Yoshioka T, Arai N, Sugaya H, Taniguchi Y, Kanamori A, Gosho M et al (2024) The effectiveness of leukocyte-poor platelet-rich plasma injections for symptomatic mild to moderate osteoarthritis of the knee with Joint Effusion or Bone Marrow lesions in a Japanese Population: a Randomized, Double-Blind, placebo-controlled clinical trial. Am J Sports Med 52(10):2493–2502. https://doi.org/10.1177/03635465241263073CrossRefPubMed

34.

Kon E, de Girolamo L, Laver L, Andriolo L, Andia I, Bastos R et al (2024) Platelet-rich plasma injections for the management of knee osteoarthritis: the ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surg Sports Traumatol Arthrosc 32(11):2938–2949. https://doi.org/10.1002/ksa.12320CrossRefPubMed

35.

Bensa A, Sangiorgio A, Boffa A, Salerno M, Moraca G, Filardo G (2024) Corticosteroid injections for knee osteoarthritis offer clinical benefits similar to hyaluronic acid and lower than platelet-rich plasma: a systematic review and meta-analysis. EFORT Open Rev 9(9):883–895. https://doi.org/10.1530/EOR-23-0198CrossRefPubMedPubMedCentral

36.

Lo Presti M, Costa GG, Agrò G, Vasco C, Boffa A, Di Martino A et al (2024) Platelet-Rich plasma injections do not improve the recovery after arthroscopic partial meniscectomy: a double-blind randomized controlled trial. Am J Sports 52(13):3198–3205. https://doi.org/10.1177/03635465241283052CrossRef

37.

Xu RD, Li JH, Zhang H, Liang HR, Duan SY, Sun M et al (2024) The combined application of pulsed electromagnetic fields and platelet-rich plasma in the treatment of early-stage knee osteoarthritis: a randomized clinical trial. Med (Baltim) 103(35):e39369. https://doi.org/10.1097/MD.0000000000039369CrossRef

38.

Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A (2013) Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med 41(2):356–364. https://doi.org/10.1177/0363546512471299CrossRefPubMed

39.

Kon E, Buda R, Filardo G, Di Martino A, Timoncini A, Cenacchi A et al (2010) Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. Knee Surg Sports Traumatol Arthrosc 18(4):472–479. https://doi.org/10.1007/s00167-009-0940-8CrossRefPubMed

40.

Boffa A, De Marziani L, Andriolo L, Di Martino A, Romandini I, Zaffagnini S et al (2024) Influence of platelet concentration on the clinical outcome of platelet-rich plasma injections in knee osteoarthritis. Am J Sports Med 52(13):3223–3231. https://doi.org/10.1177/03635465241283463CrossRefPubMedPubMedCentral

41.

Qiu M, He Y, Zhang H, Zheng Y, Shi X, Yang J (2024) Platelet-Rich plasma (PRP) based on simple and efficient Integrated Preparation precises quantitatively for skin wound repair. Int J Mol Sc 25(17):9340. https://doi.org/10.3390/ijms25179340CrossRef

42.

Kamada K, Matsushita T, Yamashita T, Matsumoto T, Iwaguro H, Kuroda R et al (2024) Factors affecting the therapeutic effects of multiple intra-articular injections of platelet-rich-plasma for knee osteoarthritis. Asia Pac J Sports Med Arthrosc Rehabil Technol 43–48. https://doi.org/10.1016/j.asmart.2024.09.006

43.

Romandini I, Boffa A, Di Martino A, Andriolo L, Cenacchi A, Sangiorgi E et al (2024) Leukocytes do not influence the safety and efficacy of platelet-rich plasma injections for the treatment of knee osteoarthritis: a double-blind randomized controlled trial. Am J Sports 52(13):3212–3222. https://doi.org/10.1177/03635465241283500CrossRef

44.

Gupta A, Viswanath A, Kumar GH (2024) Leukocyte-poor platelet-rich plasma for the management of knee osteoarthritis: a retrospective study with 12 months of Follow-Up, vol 16. Cureus, p e69662. 910.7759/cureus.69662

45.

Thompson K, Shankar DS, Huang S, Kirsch T, Campbell KA, Gonzalez-Lomas G (2024) The Effectiveness of Alpha-2-Macroglobulin Injections for Osteoarthritis of the Knee. Bull Hosp Jt Dis (2013) 82(4):245–256

46.

Zhang Q, Zhou H, Li D, Zhong Y, Zhao YF, Yan J, Zhao H (2024) The role of fibrinogen combined with platelet-rich plasma in enhancing microfracture for cartilage damage: a retrospective study of 113 patients with knee osteoarthritis. J Orthop Surg Res 19(1):669. https://doi.org/10.1186/s13018-024-05145-5CrossRefPubMedPubMedCentral

47.

Medina-Porqueres I, Martin-Garcia P, Sanz-De Diego S, Reyes-Eldblom M, Cantero-Tellez R (2019) Platelet-rich plasma for thumb carpometacarpal joint osteoarthritis in a professional pianist: case-based review. Rheumatol Int 39(12):2167–2175. https://doi.org/10.1007/s00296-019-04454-xCrossRefPubMed

48.

Maciel AP, Quispe RA, Martins LJO, Caldas RJ, Santos PSDS (2020) Clinical profile of individuals with bisphosphonate-related osteonecrosis of the jaw: an integrative review. Sao Paulo Med J 138(4):326–335. https://doi.org/10.1590/1516-3180.2019.0352.r2.15052020CrossRefPubMedPubMedCentral

49.

Guo G, Ouyang W, Wang G, Zhao W, Zhao C (2024) Clinical evaluation of platelet-rich plasma therapy for osteonecrosis of the femoral head: a systematic review and meta-analysis. PLoS ONE 19(5):e0304096. https://doi.org/10.1371/journal.pone.0304096CrossRefPubMedPubMedCentral

50.

Luan S, Wang S, Lin C, Fan S, Liu C, Ma C, Wu S (2022) Comparisons of Ultrasound-guided platelet-rich plasma intra-articular injection and extracorporeal shock Wave Therapy in Treating ARCO I-III symptomatic non-traumatic femoral head necrosis: a Randomized Controlled Clinical Trial. J Pain Res 15:341–354. https://doi.org/10.2147/JPR.S347961CrossRefPubMedPubMedCentral

51.

Callahan EA, Peyser K, Espiritu-McKay T (2024) Leukocyte-rich platelet-rich plasma for osteonecrosis of sesamoid in a Performing Artist: a Case Report. J Dance Med Sci 25:1089313X241265424. https://doi.org/10.1177/1089313X241265424CrossRef

52.

Scala VA, Kikuchi CK (2022) Sesamoid avascular necrosis and stress fracture treated with Core Decompression and Biologic Augmentation. Hawaii J Health Soc Welf 81(3 Suppl 1):16–18PubMedPubMedCentral

53.

Lyu J, Ma T, Huang X, Shi J, Huang G, Chen F et al (2023) Core decompression with β-tri-calcium phosphate grafts in combination with platelet-rich plasma for the treatment of avascular necrosis of femoral head. BMC Musculoskelet Disord 24(1):40. https://doi.org/10.1186/s12891-022-06120-zCrossRefPubMedPubMedCentral

54.

Liang D, Pei J, Zhang X, Chen X (2023) Clinical outcomes of autologous platelet-rich plasma and bone marrow mononuclear cells grafting combined with core decompression for Association Research Circulation Osseous II-IIIA stage non-traumatic osteonecrosis of the femoral head. Int Orthop 47(9):2181–2188. https://doi.org/10.1007/s00264-023-05779-wCrossRefPubMed

55.

Schneider N, Sinnott M, Patel N, Joseph R (2024) The use of platelet-rich plasma and stem cell injections in Musculoskeletal injuries. Cureus 16(5):e59970. https://doi.org/10.7759/cureus.59970CrossRefPubMedPubMedCentral

56.

Tischer T, Bode G, Buhs M, Marquass B, Nehrer S, Vogt S et al (2020) Platelet-rich plasma (PRP) as therapy for cartilage, tendon and muscle damage - German working group position statement. J Exp Orthop 7(1):64. https://doi.org/10.1186/s40634-020-00282-2CrossRefPubMedPubMedCentral

57.

de Vos RJ, Weir A, van Schie HT, Bierma-Zeinstra SM, Verhaar JA, Weinans H et al (2010) Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA 303(2):144–149. https://doi.org/10.1001/jama.2009.1986CrossRefPubMed

58.

Kearney RS, Ji C, Warwick J, Parsons N, Brown J, Harrison P et al (2021) Effect of platelet-rich plasma injection vs sham injection on Tendon Dysfunction in patients with chronic midportion Achilles Tendinopathy: a Randomized Clinical Trial. JAMA 326(2):137–144. https://doi.org/10.1001/jama.2021.6986CrossRefPubMedPubMedCentral

59.

Nauwelaers AK, Van Oost L, Peers K (2021) Evidence for the use of PRP in chronic midsubstance Achilles tendinopathy: a systematic review with meta-analysis. Foot Ankle Surg 27(5):486–495. https://doi.org/10.1016/j.fas.2020.07.009CrossRefPubMed

60.

Krogh TP, Ellingsen T, Christensen R, Jensen P, Fredberg U (2016) Ultrasound-guided injection therapy of Achilles Tendinopathy with platelet-rich plasma or saline: a Randomized, Blinded, Placebo-Controlled Trial. Am J Sports Med 44(8):1990–1997. https://doi.org/10.1177/0363546516647958CrossRefPubMed

61.

Kirschner JS, Cheng J, Hurwitz N, Santiago K, Lin E, Beatty N et al (2021) Ultrasound-guided percutaneous needle tenotomy (PNT) alone versus PNT plus platelet-rich plasma injection for the treatment of chronic tendinosis: a randomized controlled trial. PM R 13(12):1340–1349. https://doi.org/10.1002/pmrj.12583CrossRefPubMed

62.

Kruse RC, Eisenmann J, Glass NA, Petrachaianan K, Wilz L (2024) Platelet-poor vs platelet-rich plasma for the treatment of Acute Thigh muscle injuries. Am J Phys Med Rehabil. https://doi.org/10.1097/PHM.0000000000002591CrossRefPubMed

63.

Zeng L, Shi Y, Subatijang P, Zhang L, Gao J, Sun R, Jiang K (2024) Global research trends and hotspots in rheumatoid arthritis joint replacement:bibliometric analysis and visualization study. J Orthop 61:72–84. https://doi.org/10.1016/j.jor.2024.09.017CrossRefPubMed

64.

Raslan MA, Raslan SA, Shehata EM, Mahmoud AS, Sabri NA, Alzahrani KJ et al (2024) Different modalities to manage rheumatoid arthritis: an A to Z story. Future Sci OA 10(1):FSO968. https://doi.org/10.2144/fsoa-2023-0134CrossRefPubMedPubMedCentral

65.

Piramoon S, Tahoori MT, Owlia MB, Royaei MR (2024) PRP as a modulator of inflammation in FLS of RA patients by regulation of galectins and TGF-β1. Heliyon 10(1):e24036. https://doi.org/10.1016/j.heliyon.2024.e24036CrossRefPubMedPubMedCentral

66.

Badsha H, Harifi G, Murrell WD (2020) Platelet Rich plasma for treatment of rheumatoid arthritis: Case Series and Review of Literature. Case Rep Rheumatol 2020:8761485. https://doi.org/10.1155/2020/8761485CrossRefPubMedPubMedCentral

67.

Cutolo M, Soldano S, Smith V (2019) Pathophysiology of systemic sclerosis: current understanding and new insights. Expert Rev Clin Immunol 15(7):753–764. https://doi.org/10.1080/1744666X.2019.1614915CrossRefPubMed

68.

Brown M, O’Reilly S (2019) The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol 195(3):310–321. https://doi.org/10.1111/cei.13238CrossRefPubMed

69.

Condorelli AP, Ficarelli AMC, Motolese E, Alfonso Contu (2024) Platelet-rich plasma for the treatment of scleroderma-associated ulcers: a single-center experience and literature review. Dermatology Rep. https://doi.org/10.4081/dr.2024.9878CrossRef

70.

Kanemaru H, Kajihara I, Yamanaka K, Igata T, Makino T, Masuguchi S et al (2015) Platelet-rich plasma therapy is effective for the treatment of refractory skin ulcers in patients with systemic sclerosis. Mod Rheumatol 25(4):660–661. https://doi.org/10.3109/14397595.2014.924204CrossRefPubMed

71.

Pirrello R, Verro B, Grasso G, Ruscitti P, Cordova A, Giacomelli R et al (2019) Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study. Arthritis Res Ther 21(1):286. https://doi.org/10.1186/s13075-019-2062-0CrossRefPubMedPubMedCentral

72.

Schipper JAM, Verhoef LL, Schepers RH, Dijkstra PU, Stel AJ, van der Werf S et al (2024) Regenerative treatments for scleroderma in cutaneous manifestations of the face: a systematic review. Clin Exp Rheumatol 42(8):1675–1689. https://doi.org/10.55563/clinexprheumatol/y2p4ibCrossRefPubMed

73.

Virzì F, Bianca P, Giammona A, Apuzzo T, Di Franco S, Mangiapane LR et al (2017) Combined platelet-rich plasma and lipofilling treatment provides great improvement in facial skin-induced lesion regeneration for scleroderma patients. Stem Cell Res Ther 8(1):236. https://doi.org/10.1186/s13287-017-0690-3CrossRefPubMedPubMedCentral

74.

Abellan Lopez M, Philandrianos C, Daumas A, Velier M, Arcani R, Jouve E et al (2023) Assessing the effect of PRP addition to facial micro-lipofilling for patients suffering from Scleroderma: a prospective routine care analysis. Ann Chir Plast Esthet 68(2):152–161. https://doi.org/10.1016/j.anplas.2022.07.016CrossRefPubMed

75.

Todorova LN, Abadjieva T (2023) Platelet-Rich plasma in Alopecia Areata: a Case Report with a Mini Review of Literature. Cureus 15(5):e38751. https://doi.org/10.7759/cureus.38751CrossRefPubMedPubMedCentral

76.

Vladulescu D, Scurtu LG, Simionescu AA, Scurtu F, Popescu MI, Simionescu O (2023) Platelet-Rich plasma (PRP) in Dermatology: Cellular and Molecular mechanisms of Action. Biomedicines 12(1):7. https://doi.org/10.3390/biomedicines12010007CrossRefPubMedPubMedCentral

77.

Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V (2015) The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cells Transl Med 4(11):1317–1323. https://doi.org/10.5966/sctm.2015-0107CrossRefPubMedPubMedCentral

78.

Yang XS, Wang TT, Ding YX, Chen YH, Lv ZF (2024) Concentrated growth factor therapy as cosmetic treatment in discoid lupus erythematosus. J Dermatol 51(8):1125–1128. https://doi.org/10.1111/1346-8138.17114CrossRefPubMedPubMedCentral

79.

Sriram S, Sankaralingam R, Mani M, Tamilselvam TN (2016) Autologous platelet rich plasma in the management of non-healing vasculitic ulcers. Int J Rheum Dis 19(12):1331–1336. https://doi.org/10.1111/1756-185X.12914CrossRefPubMed

80.

Dimai HP, Fahrleitner-Pammer A (2022) Osteoporosis and fragility fractures: currently available pharmacological options and future directions. Best Pract Res Clin Rheumatol 36(3):101780. https://doi.org/10.1016/j.berh.2022.101780CrossRefPubMed

81.

Inbarajan A, Veeravalli PT, Seenivasan MK, Natarajan S, Sathiamurthy A, Ahmed SR et al (2021) Platelet-Rich plasma and Platelet-Rich Fibrin as a Regenerative Tool. J Pharm Bioallied Sci 13(Suppl 2):S1266–S1267. https://doi.org/10.4103/jpbs.jpbs_74_21CrossRefPubMedPubMedCentral

82.

Amiri MA, Farshidfar N, Miron RJ, Dziedzic A, Hamedani S, Daneshi S et al (2023) The potential therapeutic effects of platelet-derived biomaterials on osteoporosis: a Comprehensive Review of current evidence. Int J Biomater 2023:9980349. https://doi.org/10.1155/2023/9980349CrossRefPubMedPubMedCentral

83.

Jelin-Uhlig S, Weigel M, Ott B, Imirzalioglu C, Howaldt HP, Böttger S et al (2024) Bisphosphonate-related osteonecrosis of the Jaw and oral Microbiome: clinical risk factors, pathophysiology and treatment options. Int J Mol Sci 25(15):8053. https://doi.org/10.3390/ijms25158053CrossRefPubMedPubMedCentral

84.

Steller D, Herbst N, Pries R, Juhl D, Hakim SG (2019) Positive impact of platelet-rich plasma and platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid. Sci Rep 9(1):8310. https://doi.org/10.1038/s41598-019-43798-zCrossRefPubMedPubMedCentral

85.

Klein J, Soni C, Ayotte B, Castro-Nunez C, Feketeova E (2024) Are patients with knee osteoarthritis aware that platelet-rich plasma is a treatment option? Med (Baltim) 103(3):e36712. https://doi.org/10.1097/MD.0000000000036712CrossRef

86.

Tey RV, Haldankar P, Joshi VR, Raj R, Maradi R (2022) Variability in Platelet-Rich plasma preparations used in Regenerative Medicine: a comparative analysis. Stem Cells Int 2022:3852898. https://doi.org/10.1155/2022/3852898CrossRefPubMedPubMedCentral

87.

Lana JF, Huber SC, Purita J, Tambeli CH, Santos GS, Paulus C et al (2019) Leukocyte-rich PRP versus leukocyte-poor PRP - the role of monocyte/macrophage function in the healing cascade. J Clin Orthop Trauma 10(Suppl 1):S7–S12. https://doi.org/10.1016/j.jcot.2019.05.008CrossRefPubMedPubMedCentral

88.

Rodríguez-Merchán EC (2022) Intra-articular platelet-rich plasma injections in knee osteoarthritis: a review of their current Molecular mechanisms of Action and their degree of efficacy. Int J Mol Sci 23(3):1301. https://doi.org/10.3390/ijms23031301CrossRefPubMedPubMedCentral

89.

Saita Y, Kobayashi Y, Nishio H, Wakayama T, Fukusato S, Uchino S et al (2021) Predictors of effectiveness of platelet-rich plasma therapy for knee osteoarthritis: a retrospective cohort study. J Clin Med 10(19):4514. https://doi.org/10.3390/jcm10194514CrossRefPubMedPubMedCentral

90.

Bhan K, Singh B (2022) Efficacy of platelet-rich plasma injection in the management of Rotator Cuff Tendinopathy: a review of the current literature. Cureus 14(6):e26103. https://doi.org/10.7759/cureus.26103CrossRefPubMedPubMedCentral

91.

de Wit M, Aouad K, Elhai M, Benavent D, Bertheussen H, Blackburn S et al (2024) EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update. Ann Rheum Dis 83(11):1443–1453. https://doi.org/10.1136/ard-2024-225566CrossRefPubMed

92.

Howlader MAA, Almigdad A, Urmi JF, Ibrahim H (2023) Efficacy and safety of Hyaluronic Acid and platelet-rich plasma combination Therapy Versus platelet-rich plasma alone in treating knee osteoarthritis: a systematic review. Cureus 15(10):e47256. https://doi.org/10.7759/cureus.47256CrossRefPubMedPubMedCentral

93.

Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P (2023) The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol 23(8):495–510. https://doi.org/10.1038/s41577-023-00834-4CrossRefPubMed

94.

Jones IA, Togashi RC, Thomas Vangsness C Jr (2018) The Economics and Regulation of PRP in the Evolving Field of Orthopedic Biologics. Curr Rev Musculoskelet Med 11(4):558–565. https://doi.org/10.1007/s12178-018-9514-zCrossRefPubMedPubMedCentral

95.

Tiao J, Wang K, Herrera M, Ren R, Rosenberg AM, Cassie R et al (2024) There is wide variation in platelet-rich plasma injection pricing: a United States Nationwide Study of Top Orthopaedic Hospitals. Clin Orthop Relat Res 482(4):675–684. https://doi.org/10.1097/CORR.0000000000002864CrossRefPubMed

Title: Use of platelet-rich plasma in rheumatic diseases
Authors: Marlen Yessirkepov
Yuliya Fedorchenko
Olena Zimba
Ulzhan Mukanova
Publication date: 01-01-2025
Publisher: Springer Berlin Heidelberg
Keywords: Platelet Rich Plasma Therapy
Growth Factors
Osteoarthrosis
Osteoarthrosis
Osteonecrosis
Tendinopathy
Rheumatoid Arthritis
Systemic Sclerosis
Published in: Rheumatology International / Issue 1/2025
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-024-05776-1

Successful rituximab treatment in a seronegative rheumatoid arthritis patient with concurrent cold agglutinin syndrome and immune thrombocytopenia

Rituximab
Case Based Review

Association of nutritional status indices with gastrointestinal symptoms in systemic sclerosis: a cross-sectional study

Open Access
Systemic Sclerosis
Observational Research

Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review

Rituximab
Case Based Review

Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers

Ankylosing Spondylitis
Observational Research

COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time

Long-COVID Syndrome
Correspondence

Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review

Systemic Sclerosis
Review

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Use of platelet-rich plasma in rheumatic diseases

Abstract

Other articles of this Issue 1/2025

Successful rituximab treatment in a seronegative rheumatoid arthritis patient with concurrent cold agglutinin syndrome and immune thrombocytopenia

Association of nutritional status indices with gastrointestinal symptoms in systemic sclerosis: a cross-sectional study

Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review

Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers

COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time

Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content

Successful rituximab treatment in a seronegative rheumatoid arthritis patient with concurrent cold agglutinin syndrome and immune thrombocytopenia

Association of nutritional status indices with gastrointestinal symptoms in systemic sclerosis: a cross-sectional study

Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review

Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers

COVID-19 is a trigger of autoimmune rheumatic diseases: a hypothesis tested over time

Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review